<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-149534" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Endocrine-Related Adverse Events From Immune Checkpoint Inhibitors </title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Nava Suarez</surname>
            <given-names>Corina C.</given-names>
          </name>
          <aff>Einstein Healthcare Network</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Anastasopoulou</surname>
            <given-names>Catherine</given-names>
          </name>
          <aff>Jefferson Einstein Medical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Corina Nava Suarez declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Catherine Anastasopoulou declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>21</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-149534.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Immunomodulators are&#x000a0;agents that alter a pathway&#x000a0;controlling the activity of the immune system. Immune checkpoint inhibitors are immunotherapies employed as a novel treatment for&#x000a0;various cancers,&#x000a0;including metastatic melanoma, Hodgkin lymphoma, breast cancer, and non-small cell lung cancer, each carrying high morbidity and mortality in the setting of limited therapeutic options. Despite promising outcomes for cancer treatment, immune checkpoint inhibitors can cross-react with cells of the endocrine system and potentially cause serious endocrine immune-related adverse events.&#x000a0;</p>
        <p>Patients undergoing treatment with immune checkpoint inhibitors may develop various endocrinopathies, including&#x000a0;hypophysitis, thyroiditis, adrenal insufficiency, insulin-dependent diabetes, and calcium derangements. Specific autoantibodies may play a role in the susceptibility of a patient to this cross-reactivity. Specialized&#x000a0;evaluation and management&#x000a0;of&#x000a0;endocrinopathies&#x000a0;with hormone replacement therapy or suppression is imperative to guarantee the best possible outcomes for affected patients. Long-term monitoring and treatment guided by an endocrinologist is usually indicated.</p>
        <p>This activity&#x000a0;reviews the possible pathophysiology of immune checkpoint inhibitor-induced endocrinopathies, the epidemiology of these adverse events, and specific evaluation and management of the hormonal axes involved. The activity also highlights the&#x000a0;role of the interprofessional, multidisciplinary team required to care for patients with immunomodulator-induced&#x000a0;endocrine disorders.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Assess the risk of developing an immune checkpoint inhibitor-induced endocrine-related adverse event.</p></list-item><list-item><p>Differentiate the symptoms and signs of commonly encountered endocrinopathies secondary to the use of immune checkpoint inhibitors.</p></list-item><list-item><p>Employ best practices to assess and manage various endocrine-related adverse events in patients treated with immune checkpoint inhibitors.</p></list-item><list-item><p>Develop and implement interprofessional team strategies to improve outcomes for patients with immune checkpoint inhibitor-induced endocrinopathies.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=149534&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=149534">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-149534.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Immune system modulators, or immunomodulators, are agents that affect or change a pathway controlling the activity of the immune system. These substances either activate or inhibit cells and signaling cascades to stimulate or suppress the reactivity of the immune system. Immune checkpoint inhibitors (ICIs) are a specific type of immunomodulatory antibody.&#x000a0;ICIs have opened the door to treating aggressive malignancies previously considered untreatable. ICIs have become the standard of care for many metastatic cancers.<xref ref-type="bibr" rid="article-149534.r1">[1]</xref>&#x000a0;However, the pathways targeted by immunomodulators may be found in&#x000a0;many organ systems, and these agents are nonselective for cancer cells. This lack of selectivity may cause cross-reactivity resulting in unwanted immune-related adverse events&#x000a0;(IrAEs).<xref ref-type="bibr" rid="article-149534.r2">[2]</xref>&#x000a0;The endocrine system appears especially susceptible to this cross-reactivity, often resulting in new-onset endocrinopathies with ICI use.<xref ref-type="bibr" rid="article-149534.r3">[3]</xref><xref ref-type="bibr" rid="article-149534.r4">[4]</xref></p>
      </sec>
      <sec id="article-149534.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Agents employed as ICIs are&#x000a0;frequently monoclonal antibodies that block proteins and receptors T cells use to attach to antigen-presenting cells. By blocking these proteins and receptors, ICIs inhibit a stop signal that negatively affects the immune system in normal circumstances. Inhibition of the stop signal allows the T cell to become activated, unleashing its response and instructing the T cell to attack cancer cells.<xref ref-type="bibr" rid="article-149534.r5">[5]</xref>&#x000a0;</p>
        <p>One example of a T-cell receptor blocked by an ICI is cytotoxic T lymphocyte-associated antigen-4 (CTLA-4). CTLA-4 normally antagonizes T-cell activity and prevents continuous stimulation of T cells. Cancer cells hide from the immune system using CTLA-4 pathways. The ICIs ipilimumab and tremelimumab are human monoclonal antibodies that prevent the inhibitory effect of CTLA-4 and allow T cells to become activated against cancer cells.</p>
        <p>Another pathway affected by ICIs&#x000a0;involves the programmed cell death-1 receptor (PD-1) and programmed death-ligand-1 (PDL-1).<xref ref-type="bibr" rid="article-149534.r5">[5]</xref>&#x000a0;PD-1 inhibits the overactivation of T cells during infections.&#x000a0;Blockage of PD-1 allows a more robust immune response against certain types of cancer. The ICIs nivolumab and pembrolizumab are anti-PD-1 monoclonal antibodies.</p>
      </sec>
      <sec id="article-149534.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Endocrinopathies are one of the most commonly encountered IrAEs secondary to ICI use. The reported incidence of newly developed endocrinopathies in patients undergoing ICI treatment approximates 10%.<xref ref-type="bibr" rid="article-149534.r6">[6]</xref><xref ref-type="bibr" rid="article-149534.r7">[7]</xref>&#x000a0;The presentation of the endocrinopathy is dictated by the type of ICI therapy; some endocrine organs are more affected by specific agents or combined therapies.</p>
        <p>Endocrinopathies secondary to ICI use may include hypophysitis, thyroiditis, adrenal insufficiency, autoimmune diabetes, and calcium abnormalities. The most frequent endocrinopathies secondary to ICIs are hypothyroidism and hyperthyroidism, with a combined incidence of approximately 15%. These thyroid derangements are seen predominately when employing anti-PD-1 or anti-PD-L1 agents and are more common in females.<xref ref-type="bibr" rid="article-149534.r7">[7]</xref></p>
        <p>Hypophysitis is most common in older male patients exposed to anti-CTLA-4 agents. Adrenal insufficiency has also been reported in older males, albeit less frequently than hypophysitis. Adrenal insufficiency&#x000a0;appears to have a stronger association with&#x000a0;the use of anti-PD-1 antibodies than with CTLA-4 inhibitors&#x000a0;<xref ref-type="bibr" rid="article-149534.r7">[7]</xref>.&#x000a0;</p>
        <p>Endocrinopathies usually occur after at least 9 weeks of treatment with ICIs. Most adverse events happen within the first&#x000a0;9 months of initiating ICI therapy.<xref ref-type="bibr" rid="article-149534.r6">[6]</xref>&#x000a0;However,&#x000a0;endocrinopathies can emerge years after the initiation of&#x000a0; ICI therapy,&#x000a0;complicating the differentiation of the endocrinopathy from the adverse effects of other medications or cancer-related symptoms.&#x000a0;</p>
      </sec>
      <sec id="article-149534.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The exact pathogenic mechanism of ICI-induced endocrine-related&#x000a0;IrAEs is not well understood. However, overstimulation of T cells by ICIs can lead to reactive autoimmunity in cells that express the same receptors as cancer cells.</p>
        <p>It is hypothesized that CTLA-4 is expressed in some pituitary cells and that PD-L1 is&#x000a0;expressed in thyroid, pituitary, and pancreatic tissues. This expression opens the door to possible cross-reactivity and T-cell&#x02013;mediated toxicity in these organs with ICIs.<xref ref-type="bibr" rid="article-149534.r4">[4]</xref><xref ref-type="bibr" rid="article-149534.r8">[8]</xref>&#x000a0;Case reports have described adrenal and parathyroid&#x000a0;disorders&#x000a0;related to the use of monoclonal antibodies, but these endocrinopathies appear to be less common.<xref ref-type="bibr" rid="article-149534.r9">[9]</xref><xref ref-type="bibr" rid="article-149534.r10">[10]</xref>&#x000a0;</p>
        <p>Another hypothesis is based on the concept of preexisting specific endocrine autoantibodies as conditioning for endocrine-related IrAEs. Labadzhyan&#x000a0;et al&#x000a0;performed a retrospective study over 36 weeks evaluating the presence of endocrine-related antibodies in adults before initiating ICI treatment&#x000a0;with the development of endocrinopathies. Of the 60 patients evaluated, 11 were found to have preexisting endocrine autoantibodies and 3 seroconverted during ICI therapy. Endocrine autoantibodies were significantly associated with endocrine-related adverse effects, presenting the possibility of&#x000a0;endocrine autoantibodies as predictive and follow-up markers for IrAEs.<xref ref-type="bibr" rid="article-149534.r11">[11]</xref><xref ref-type="bibr" rid="article-149534.r12">[12]</xref><xref ref-type="bibr" rid="article-149534.r13">[13]</xref></p>
      </sec>
      <sec id="article-149534.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>The presentation of IrAEs will depend on the specific endocrine gland and to what extent it is affected, as well as the dose and duration of the administered treatment. Patients with ICI-induced endocrinopathies may present with nonspecific symptoms&#x000a0;challenging to distinguish from cancer symptoms or chemotherapy-related side effects.</p>
        <p>
<bold>The Thyroid</bold>
</p>
        <p>Approximately 2.6% to 6% of patients treated with ICIs will develop thyroid dysfunction. Thyroid endocrinopathies occur mainly in the setting of anti-PD-1, anti-PD-L1, and combined therapy at rates of 40%, 6% to 11%, and 20%, respectively.<xref ref-type="bibr" rid="article-149534.r7">[7]</xref>&#x000a0;Patients with ICI-induced thyroid dysfunction&#x000a0;often present with mild-to-moderate symptoms&#x000a0;of hypothyroidism or hyperthyroidism, including presentations similar to Hashimoto or Graves thyroiditis. However, symptoms of hypothyroidism are most frequent.<xref ref-type="bibr" rid="article-149534.r14">[14]</xref>&#x000a0;Rarely, patients may present with symptoms suggestive of destructive thyroiditis, characterized by an initial transient thyrotoxicosis followed by subclinical or complete hypothyroidism and, finally, recovery of normal thyroid function. Unfortunately, full recovery of thyroid function may&#x000a0;not occur, and long-term thyroxine supplementation will be needed.<xref ref-type="bibr" rid="article-149534.r7">[7]</xref><xref ref-type="bibr" rid="article-149534.r15">[15]</xref></p>
        <p>
<bold>The Pituitary Gland</bold>
</p>
        <p>The pituitary gland is most commonly affected by anti-CTLA-4 antibodies or combined therapy and less frequently by anti-PD-1 or anti-PD-L1 antibodies. Symptoms of pituitary dysfunction usually develop 4 to 10 weeks after treatment initiation but can develop many as 22 weeks after treatment initiation or beyond treatment discontinuation.<xref ref-type="bibr" rid="article-149534.r16">[16]</xref><xref ref-type="bibr" rid="article-149534.r17">[17]</xref>&#x000a0;Patients may present with&#x000a0;hypophysitis,&#x000a0;deficiencies in&#x000a0;multiple hormonal axes, and enlargement of the adenohypophysis or as isolated adrenocorticotropic hormone (ACTH) deficiency without pituitary enlargement.<xref ref-type="bibr" rid="article-149534.r18">[18]</xref><xref ref-type="bibr" rid="article-149534.r19">[19]</xref>. A male-to-female predominance of 4:1 has been reported for cases of hypophysitis.<xref ref-type="bibr" rid="article-149534.r20">[20]</xref></p>
        <p>Once ACTH hyposecretion and corticotroph impairment develop, recovery of the hypothalamic-pituitary-adrenal axis&#x000a0;may not occur with discontinuation of ICIs, resulting in long-term clinical repercussions and the need for chronic glucocorticoid treatment.<xref ref-type="bibr" rid="article-149534.r16">[16]</xref>&#x000a0;</p>
        <p>While secondary adrenal insufficiency is the most common pituitary-related IrAE, central hypothyroidism, and secondary hypogonadism are also commonly seen.<xref ref-type="bibr" rid="article-149534.r17">[17]</xref>&#x000a0;Headaches are the most common symptom of ICI-induced pituitary-related dysfunction reported in the literature regardless of the cell line affected or hormonal deficiency.<xref ref-type="bibr" rid="article-149534.r8">[8]</xref><xref ref-type="bibr" rid="article-149534.r16">[16]</xref><xref ref-type="bibr" rid="article-149534.r17">[17]</xref>. There are rare case reports of ICI-induced neurohypophyseal dysfunction resulting in diabetes insipidus.<xref ref-type="bibr" rid="article-149534.r21">[21]</xref></p>
        <p>
<bold>The Adrenal Gland</bold>
</p>
        <p>Primary adrenal insufficiency resulting in glucocorticoid deficiency is a rare IrAE, and the diagnosis is especially challenging if clinicians are unfamiliar with this endocrinopathy. Patients can present with nonspecific symptoms of fatigue, malaise, and muscle weakness, all common in patients undergoing cancer treatment. While developing hyponatremia, hyperkalemia, hypoglycemia, or hyperpigmentation might distinguish primary adrenal insufficiency from other diagnoses, the absence of these signs and symptoms does not exclude adrenal dysfunction. Some patients with adrenal insufficiency can be completely asymptomatic until a physical or emotional stressor unmasks the disorder; failure to identify and treat an adrenal crisis can lead to life-threatening events and death.<xref ref-type="bibr" rid="article-149534.r10">[10]</xref></p>
        <p>
<bold>Diabetes</bold>
</p>
        <p>The new onset of autoimmune&#x000a0;diabetes is an uncommon complication reported in &#x0003c;1% of patients undergoing ICI therapy. Nonetheless, the presentation of autoimmune diabetes in those affected is usually severe; the onset of insulin deficiency is usually rapid and profound. Symptoms of hyperglycemia, such as polyuria and polydipsia, can develop quickly and become life-threatening or fulminant. Severe hyperglycemia with diabetic ketoacidosis, hyperosmolar hyperglycemic state, or a combination are frequent signs of the initial presentation of ICI-induced autoimmune diabetes.<xref ref-type="bibr" rid="article-149534.r4">[4]</xref><xref ref-type="bibr" rid="article-149534.r22">[22]</xref></p>
        <p>
<bold>Calcium Derangements</bold>
</p>
        <p>Isolated case reports have described acute symptomatic hypocalcemia from ICI-induced parathyroid hormone deficiency.<xref ref-type="bibr" rid="article-149534.r23">[23]</xref>&#x000a0;More&#x000a0;research is needed to understand the exact mechanism&#x000a0;of ICI-induced hypocalcemia; autoantibodies may activate the calcium-sensing receptor in some cases.<xref ref-type="bibr" rid="article-149534.r24">[24]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-149534.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Regardless of the endocrinopathy, laboratory evaluation ideally should precede imaging studies. The measurement of specific hormone levels is dictated by the underlying endocrinopathy suspected.</p>
        <p>
<bold>The Thyroid Gland</bold>
</p>
        <p>The first step in evaluating suspected thyroid dysfunction is obtaining serum thyroid-stimulating hormone (TSH) and free thyroxine (FT4) levels. Surveillance of thyroid function should be performed in every patient undergoing treatment with ICIs.<xref ref-type="bibr" rid="article-149534.r6">[6]</xref>&#x000a0;A suppressed TSH with an elevated FT4 is characteristic of hyperthyroidism. Measurement of total serum triiodothyronine (TT3) levels may be helpful when FT4 levels&#x000a0;are not elevated as expected, and T3 thyrotoxicosis is suspected. Contrarily, a high TSH with a low FT4 is a typical finding of primary hypothyroidism.<xref ref-type="bibr" rid="article-149534.r6">[6]</xref><xref ref-type="bibr" rid="article-149534.r15">[15]</xref>&#x000a0;A thyroid ultrasound can better characterize glandular morphology and exclude thyroid nodules and other diagnoses in patients with presumptive hyperthyroidism.<italic toggle="yes">&#x000a0;</italic>Most patients with ICI-induced thyroiditis have increased F-18 fluorodeoxyglucose (FDG) uptake in the thyroid on&#x000a0;positron emission tomography (PET/CT),&#x000a0;and this imaging modality can be considered as&#x000a0;a part of the evaluation.<xref ref-type="bibr" rid="article-149534.r25">[25]</xref></p>
        <p>
<bold>The Pituitary Gland</bold>
</p>
        <p>Given its potentially catastrophic consequences, the most essential step in the initial evaluation of pituitary gland dysfunction is to&#x000a0;assess for adrenal insufficiency. While measuring early morning cortisol levels is usually the first step, treatment for adrenal insufficiency should not be delayed by a diagnostic evaluation if the patient presents with symptoms of an impending adrenal crisis. An 8 AM cortisol level of &#x0003c;3 mcg/dL confirms the diagnosis of adrenal insufficiency in a patient with congruent signs and symptoms, and an 8 AM cortisol level &#x0003e;18 mcg/dL excludes it. Levels between 3 and 18 mcg/dL are harder to interpret; complete&#x000a0;or partial adrenal insufficiency remains a possible diagnosis. A confirmatory cosyntropin-stimulation test can be performed in these cases&#x000a0;to confirm&#x000a0;a diagnosis of adrenal insufficiency. A low or normal serum ACTH level is expected in central adrenal insufficiency, whereas a high serum ACTH level is characteristic of primary adrenal insufficiency.<xref ref-type="bibr" rid="article-149534.r10">[10]</xref>&#x000a0;Performing a cosyntropin-stimulation test can miss early cases of secondary adrenal insufficiency during acute hypophysitis, as the adrenal glands may still be able to respond to ACTH stimulation.</p>
        <p>As opposed to primary hypothyroidism, TSH&#x000a0;has no diagnostic value in secondary hypothyroidism; either low&#x000a0;or high TSH levels can be seen despite thyroid hormone deficiency. A serum FT4 should be measured in this circumstance. Evaluation of pituitary function should also include growth hormone (GH) and insulin growth factor-1 (IGF-1) levels to exclude GH deficiency, and luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels along with testosterone levels in men and estrogen levels in premenopausal women are required to evaluate for secondary hypogonadism&#x000a0;<xref ref-type="bibr" rid="article-149534.r6">[6]</xref>.&#x000a0;</p>
        <p>Magnetic resonance imaging (MRI) of the brain with a dedicated pituitary protocol should be obtained when pituitary involvement is suspected. Enlargement of the pituitary gland, post-contrast enhancement, and stalk thickening are typical findings.<xref ref-type="bibr" rid="article-149534.r7">[7]</xref>&#x000a0;However, the absence of imaging abnormalities does not exclude the diagnosis.<xref ref-type="bibr" rid="article-149534.r6">[6]</xref></p>
        <p>
<bold>Diabetes</bold>
</p>
        <p>In cases of hyperglycemia and insulin-dependent diabetes, measurement of hemoglobin A1c, serum blood glucose, and the autoantibodies, glutamic acid decarboxylase (GAD), islet antigen-2 (IA-2), and zinc transporter-8 (ZnT8), can be obtained to establish the diagnosis. Autoantibodies are associated with the most severe hyperglycemia at presentation.<xref ref-type="bibr" rid="article-149534.r4">[4]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-149534.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Independent of the endocrine organ affected, ICI-induced endocrine-related&#x000a0;adverse events are classified by the severity of signs and symptoms.&#x000a0;Treatment should be individualized for each specific case.</p>
        <p>The severity of signs and symptoms is classified from Grades 1 to 5. Grade 1 represents very mild symptoms, and Grade 5 is reserved for patients who died due to complications. When endocrinopathies occur, ICIs may be withheld until hormone replacement has begun, especially in patients with more severe presentations.<xref ref-type="bibr" rid="article-149534.r26">[26]</xref><xref ref-type="bibr" rid="article-149534.r27">[27]</xref></p>
        <p>It is imperative to treat adrenal insufficiency before&#x000a0;initiating other hormone supplementation.&#x000a0;While central adrenal insufficiency is managed with glucocorticoids, primary adrenal insufficiency requires the addition of mineralocorticoids.<xref ref-type="bibr" rid="article-149534.r19">[19]</xref><xref ref-type="bibr" rid="article-149534.r26">[26]</xref></p>
        <p>Replacement&#x000a0;levothyroxine is indicated in cases of hypothyroidism. Beta-blockers are recommended for the symptomatic relief of thyrotoxicosis. Frequent measurement of thyroid function tests every&#x000a0;2 to 3 weeks is advised by the American Society of Clinical Oncology (ASCO) as thyrotoxicosis can be transient.<xref ref-type="bibr" rid="article-149534.r26">[26]</xref>&#x000a0;Hyperthyroidism that persists beyond 6 weeks is usually managed with medical thyroid suppression.&#x000a0;</p>
        <p>For patients with autoimmune diabetes, insulin is the preferred therapy, especially in cases of diabetic ketoacidosis or hyperosmolar state.<xref ref-type="bibr" rid="article-149534.r7">[7]</xref>&#x000a0;</p>
        <p>ASCO recommends that all patients be closely monitored while taking hormonal supplementation, and the involvement of an endocrinologist should be considered to help with the dose titration and additional management, especially in patients with adrenal or pituitary involvement.<xref ref-type="bibr" rid="article-149534.r26">[26]</xref></p>
      </sec>
      <sec id="article-149534.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The signs and symptoms associated with endocrinopathies can be vague and misleading. Many patients undergoing cancer treatment develop fatigue, malaise, generalized weakness, or myopathies secondary to chemotherapy treatment. These symptoms are nonspecific and resemble those of adrenal insufficiency or hypothyroidism. Patients diagnosed with cancer undergoing chemotherapy have a higher incidence of depression and anxiety related to their medical treatment; associated symptoms of fatigue, weight loss, and palpitations can mimic those of IrAEs. The diagnosis of endocrinopathies can be challenging if clinicians are unfamiliar with the potential toxic effect of ICIs.</p>
        <p>Additionally, the high doses of corticosteroids frequently used in chemotherapy regimens may potentially suppress the hypothalamic-pituitary-adrenal axis and cause chronic secondary adrenal insufficiency, complicating the diagnosis of ICI-induced superimposed adrenal insufficiency. The baseline cortisol level of these patients will be unreliable.</p>
      </sec>
      <sec id="article-149534.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The clinical resolution of an endocrinopathy will vary depending on the gland affected and the extent of the effect. Unfortunately, many endocrine-related adverse effects lead to chronic deficiencies requiring lifelong supplementation of affected hormones.<xref ref-type="bibr" rid="article-149534.r7">[7]</xref>&#x000a0;</p>
        <p>However, anterior pituitary hormones are not always affected at a similar magnitude as end-organ hormones, and recovery varies from axis to axis. While recovery of thyroid function has been described in the literature, other endocrine systems may be less likely to recover. Hypogonadism and ACTH-hyposecretion seem persistent in most described cases.<xref ref-type="bibr" rid="article-149534.r16">[16]</xref>&#x000a0;Insulin deficiency in autoimmune diabetes also appears permanent in most patients.<xref ref-type="bibr" rid="article-149534.r6">[6]</xref>&#x000a0;</p>
        <p>Although quality of life can be negatively affected in patients with endocrinopathies, most patients can have a reasonably normal life with hormone supplementation.</p>
      </sec>
      <sec id="article-149534.s11" sec-type="Complications">
        <title>Complications</title>
        <p>Depending on the affected organ, misdiagnosed or mismanaged patients can have catastrophic consequences from endocrine-related adverse events, as the development of adrenal insufficiency or insulin-dependent diabetes can rapidly progress and become life-threatening if it is not recognized and treated promptly.</p>
      </sec>
      <sec id="article-149534.s12" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Immune checkpoint inhibitors are immunomodulating agents frequently used in the treatment of various malignancies. Although&#x000a0;ICIs help the immune system attack cancer cells, unfortunately, the immune system may also attack normal body cells through a process&#x000a0;of "cross-reactivity." Endocrine glands are&#x000a0;a potential target of this cross-reactivity, releasing too much or too little hormone if affected. Patients who develop ICI-induced endocrine-related&#x000a0;adverse effects will experience different symptoms, which are dictated by the gland(s) affected and the degree of the effect.</p>
        <p>Patients&#x000a0;must be educated about the potential risk of adverse effects when using immunomodulating ICIs to facilitate the reporting of suspicious symptoms and signs. It is essential that patients have frequent assessments by their primary care practitioner and oncologist to identify and evaluate new symptoms and signs. Specialty care practitioners, such as an endocrinologist, may be required to further evaluate patients, establish a diagnosis, and mange treatment regimens.</p>
      </sec>
      <sec id="article-149534.s13" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>The development of an ICI-induced endocrine-related IrAEs requires an&#x000a0;interprofessional, multidisciplinary team to evaluate and treat affected patients to optimize clinical outcomes. Recognition of ICI-induced endocrinopathies may be challenging given the vague symptomatology, but the consequences can be life-threatening if the condition goes unrecognized. The American&#x000a0;Society of Clinical Oncology expert guidelines recommend the involvement of an endocrinologist&#x000a0;in the care of any patient who develops an endocrine-related adverse event, particularly in pituitary or adrenal compromise&#x000a0;cases requiring&#x000a0;a more aggressive approach to improve outcomes and minimize morbidity and mortality.<xref ref-type="bibr" rid="article-149534.r26">[26]</xref></p>
        <p>In addition to these recommendations, pharmacists are vital as they can help with dose adjustment, alert about potential drug-to-drug interactions, and medication substitutions. A palliative care specialist, a psychologist, and spiritual services are valuable to cancer patients and their families. They can help to mitigate both physical and emotional pain and offer support when challenging decisions are to be made. Nurses are vital in the diagnosis and care of patients who suffers IrAEs. They are in close contact with patients and their families as they take the vital signs, administer treatment, and educate them. Nurses are usually among the first people the patient will inform about their symptoms, so they must be aware of the common symptomatology involving IrAEs.&#x000a0;</p>
        <p>The management of endocrine disorders does not stop after the initial presentation has improved. Still, long-term monitoring of hormonal function and chronic hormone supplementation or suppression therapies will likely be needed to ensure the best potential outcome.</p>
      </sec>
      <sec id="article-149534.s14">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=149534&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=149534">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/hormones-and-body-chemistry/endocrine-related-adverse-events-from-immune-checkpoint-inhibitors/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=149534">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/149534/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=149534">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-149534.s15">
        <title>References</title>
        <ref id="article-149534.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jain</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mishra</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Shyam</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Shankar</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Immunotherapeutic and their immunological aspects: Current treatment strategies and agents.</article-title>
            <source>Natl J Maxillofac Surg</source>
            <year>2022</year>
            <season>Sep-Dec</season>
            <volume>13</volume>
            <issue>3</issue>
            <fpage>322</fpage>
            <page-range>322-329</page-range>
            <pub-id pub-id-type="pmid">36683928</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149534.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cho</surname>
                <given-names>HW</given-names>
              </name>
              <name>
                <surname>Min</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Hong</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Song</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>NW</given-names>
              </name>
            </person-group>
            <article-title>Application of Immune Checkpoint Inhibitors in Gynecological Cancers: What Do Gynecologists Need to Know before Using Immune Checkpoint Inhibitors?</article-title>
            <source>Int J Mol Sci</source>
            <year>2023</year>
            <month>Jan</month>
            <day>04</day>
            <volume>24</volume>
            <issue>2</issue>
            <pub-id pub-id-type="pmid">36674491</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149534.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Paragliola</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Torino</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Barnabei</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Iannantuono</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Corsello</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Locantore</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Corsello</surname>
                <given-names>SM</given-names>
              </name>
            </person-group>
            <article-title>Bone Metabolism Effects of Medical Therapy in Advanced Renal Cell Carcinoma.</article-title>
            <source>Cancers (Basel)</source>
            <year>2023</year>
            <month>Jan</month>
            <day>15</day>
            <volume>15</volume>
            <issue>2</issue>
            <pub-id pub-id-type="pmid">36672478</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149534.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhang</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bi</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ding</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Jiao</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Combined diabetic ketoacidosis and hyperosmolar hyperglycemic state in type 1 diabetes mellitus induced by immune checkpoint inhibitors: Underrecognized and underreported emergency in ICIs-DM.</article-title>
            <source>Front Endocrinol (Lausanne)</source>
            <year>2022</year>
            <volume>13</volume>
            <fpage>1084441</fpage>
            <pub-id pub-id-type="pmid">36686495</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149534.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Liu</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>HJ</given-names>
              </name>
            </person-group>
            <article-title>A Review of the Pharmacokinetic Characteristics of Immune Checkpoint Inhibitors and Their Clinical Impact Factors.</article-title>
            <source>Pharmgenomics Pers Med</source>
            <year>2023</year>
            <volume>16</volume>
            <fpage>29</fpage>
            <page-range>29-36</page-range>
            <pub-id pub-id-type="pmid">36714524</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149534.r6">
          <label>6</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Elshimy</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Raj</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Akturk</surname>
                <given-names>HK</given-names>
              </name>
              <name>
                <surname>Schriber</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sisterna</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ahmad</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Jacob</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Michels</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Correa</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <chapter-title>Immune Checkpoint Inhibitors Related Endocrine Adverse Events</chapter-title>
            <person-group person-group-type="editor">
              <name>
                <surname>Feingold</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Anawalt</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Blackman</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Boyce</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chrousos</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Corpas</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>de Herder</surname>
                <given-names>WW</given-names>
              </name>
              <name>
                <surname>Dhatariya</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Dungan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hofland</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kalra</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kaltsas</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kapoor</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Koch</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kopp</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Korbonits</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kovacs</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Kuohung</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Laferr&#x000e8;re</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Levy</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>McGee</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>McLachlan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>New</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Purnell</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sahay</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Singer</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Sperling</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Stratakis</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Trence</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>DP</given-names>
              </name>
            </person-group>
            <source>Endotext [Internet]</source>
            <publisher-name>MDText.com, Inc.</publisher-name>
            <publisher-loc>South Dartmouth (MA)</publisher-loc>
            <year>2022</year>
            <month>1</month>
            <day>21</day>
            <pub-id pub-id-type="pmid">35129941</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149534.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Spagnolo</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Giuffrida</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Cannav&#x000f2;</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Franchina</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Silvestris</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ruggeri</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Santarpia</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Management of Endocrine and Metabolic Toxicities of Immune-Checkpoint Inhibitors: From Clinical Studies to a Real-Life Scenario.</article-title>
            <source>Cancers (Basel)</source>
            <year>2022</year>
            <month>Dec</month>
            <day>30</day>
            <volume>15</volume>
            <issue>1</issue>
            <pub-id pub-id-type="pmid">36612243</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149534.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cooksley</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Knight</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Lindsay</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ho</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Higham</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lorigan</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Adam</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Immune checkpoint inhibitor-mediated hypophysitis: no place like home.</article-title>
            <source>Clin Med (Lond)</source>
            <year>2023</year>
            <month>Jan</month>
            <volume>23</volume>
            <issue>1</issue>
            <fpage>81</fpage>
            <page-range>81-84</page-range>
            <pub-id pub-id-type="pmid">36697002</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149534.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lupi</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Brancatella</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cetani</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Latrofa</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Kemp</surname>
                <given-names>EH</given-names>
              </name>
              <name>
                <surname>Marcocci</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Activating Antibodies to The Calcium-sensing Receptor in Immunotherapy-induced Hypoparathyroidism.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2020</year>
            <month>May</month>
            <day>01</day>
            <volume>105</volume>
            <issue>5</issue>
            <pub-id pub-id-type="pmid">32112105</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149534.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kurokawa</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Mitsuishi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Shimada</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ito</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ogiwara</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Miura</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Asao</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ko</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Shukuya</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Shibayama</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Goto</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Takahashi</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Clinical characteristics of adrenal insufficiency induced by pembrolizumab in non-small-cell lung cancer.</article-title>
            <source>Thorac Cancer</source>
            <year>2023</year>
            <month>Feb</month>
            <volume>14</volume>
            <issue>5</issue>
            <fpage>442</fpage>
            <page-range>442-449</page-range>
            <pub-id pub-id-type="pmid">36523162</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149534.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Labadzhyan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wentzel</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hamid</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Chow</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Piro</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Melmed</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Endocrine Autoantibodies Determine Immune Checkpoint Inhibitor-induced Endocrinopathy: A Prospective Study.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2022</year>
            <month>Jun</month>
            <day>16</day>
            <volume>107</volume>
            <issue>7</issue>
            <fpage>1976</fpage>
            <page-range>1976-1982</page-range>
            <pub-id pub-id-type="pmid">35303106</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149534.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Okada</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Iwama</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Okuji</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kobayashi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Yasuda</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Wada</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Onoue</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Goto</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sugiyama</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tsunekawa</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Takagi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hagiwara</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ito</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Suga</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Banno</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hase</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Morise</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kanda</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yokota</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hashimoto</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ando</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fujimoto</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Nagino</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kodera</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Fujishiro</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hibi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Sone</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kiyoi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Gotoh</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ando</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Akiyama</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hasegawa</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Arima</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Anti-thyroid antibodies and thyroid echo pattern at baseline as risk factors for thyroid dysfunction induced by anti-programmed cell death-1 antibodies: a prospective study.</article-title>
            <source>Br J Cancer</source>
            <year>2020</year>
            <month>Mar</month>
            <volume>122</volume>
            <issue>6</issue>
            <fpage>771</fpage>
            <page-range>771-777</page-range>
            <pub-id pub-id-type="pmid">32009131</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149534.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shalit</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sarantis</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Koustas</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Trifylli</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Matthaios</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Karamouzis</surname>
                <given-names>MV</given-names>
              </name>
            </person-group>
            <article-title>Predictive Biomarkers for Immune-Related Endocrinopathies following Immune Checkpoint Inhibitors Treatment.</article-title>
            <source>Cancers (Basel)</source>
            <year>2023</year>
            <month>Jan</month>
            <day>06</day>
            <volume>15</volume>
            <issue>2</issue>
            <pub-id pub-id-type="pmid">36672324</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149534.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yuen</surname>
                <given-names>KCJ</given-names>
              </name>
              <name>
                <surname>Samson</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Bancos</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Gosmanov</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Jasim</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fecher</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Weber</surname>
                <given-names>JS</given-names>
              </name>
            </person-group>
            <article-title>American Association of Clinical Endocrinology Disease State Clinical Review: Evaluation and Management of Immune Checkpoint Inhibitor-Mediated Endocrinopathies: A Practical Case-Based Clinical Approach.</article-title>
            <source>Endocr Pract</source>
            <year>2022</year>
            <month>Jul</month>
            <volume>28</volume>
            <issue>7</issue>
            <fpage>719</fpage>
            <page-range>719-731</page-range>
            <pub-id pub-id-type="pmid">35477029</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149534.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wu</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Xiong</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Bao</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Immune checkpoint blockade PD-1 therapy for primary liver cancer: incidence and influencing factors of thyroid dysfunction.</article-title>
            <source>Infect Agent Cancer</source>
            <year>2022</year>
            <month>Dec</month>
            <day>29</day>
            <volume>17</volume>
            <issue>1</issue>
            <fpage>64</fpage>
            <pub-id pub-id-type="pmid">36581947</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149534.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kassi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Angelousi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Asonitis</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Diamantopoulos</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Anastasopoulou</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Papaxoinis</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kokkinos</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Giovanopoulos</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Kyriakakis</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Petychaki</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Savelli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Benopoulou</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Gogas</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Endocrine-related adverse events associated with immune-checkpoint inhibitors in patients with melanoma.</article-title>
            <source>Cancer Med</source>
            <year>2019</year>
            <month>Nov</month>
            <volume>8</volume>
            <issue>15</issue>
            <fpage>6585</fpage>
            <page-range>6585-6594</page-range>
            <pub-id pub-id-type="pmid">31518074</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149534.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jessel</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Weiss</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Austin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mahajan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Etts</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Aizenbud</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Perdigoto</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Hurwitz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sznol</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Herold</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Kluger</surname>
                <given-names>HM</given-names>
              </name>
            </person-group>
            <article-title>Immune Checkpoint Inhibitor-Induced Hypophysitis and Patterns of Loss of Pituitary Function.</article-title>
            <source>Front Oncol</source>
            <year>2022</year>
            <volume>12</volume>
            <fpage>836859</fpage>
            <pub-id pub-id-type="pmid">35350573</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149534.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mahzari</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Arnaout</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lochnan</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Immune checkpoint inhibitor therapy associated hypophysitis.</article-title>
            <source>Clin Med Insights Endocrinol Diabetes</source>
            <year>2015</year>
            <volume>8</volume>
            <fpage>21</fpage>
            <page-range>21-8</page-range>
            <pub-id pub-id-type="pmid">25861234</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149534.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lin</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>LZ</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>LX</given-names>
              </name>
              <name>
                <surname>Fang</surname>
                <given-names>CT</given-names>
              </name>
            </person-group>
            <article-title>Isolated adrenocorticotropic hormone deficiency associated with sintilimab therapy in a patient with advanced lung adenocarcinoma: a case report and literature review.</article-title>
            <source>BMC Endocr Disord</source>
            <year>2022</year>
            <month>Sep</month>
            <day>24</day>
            <volume>22</volume>
            <issue>1</issue>
            <fpage>239</fpage>
            <pub-id pub-id-type="pmid">36153581</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149534.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lu</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Gao</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Immune Checkpoint Inhibitor-related Endocrinopathies.</article-title>
            <source>J Transl Int Med</source>
            <year>2022</year>
            <month>Mar</month>
            <volume>10</volume>
            <issue>1</issue>
            <fpage>9</fpage>
            <page-range>9-14</page-range>
            <pub-id pub-id-type="pmid">35702188</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149534.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barnabei</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Strigari</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Corsello</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Paragliola</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Falzone</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Salvatori</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Corsello</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Torino</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Immune Checkpoint Inhibitor-Induced Central Diabetes Insipidus: Looking for the Needle in the Haystack or a Very Rare Side-Effect to Promptly Diagnose?</article-title>
            <source>Front Oncol</source>
            <year>2022</year>
            <volume>12</volume>
            <fpage>798517</fpage>
            <pub-id pub-id-type="pmid">35311088</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149534.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>de Carlos</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zabalza</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Garcia</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Marti</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ayarza-Marien</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Yoldi</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Atezolizumab induced new-onset type 1 diabetes mellitus.</article-title>
            <source>J Oncol Pharm Pract</source>
            <year>2023</year>
            <month>Jul</month>
            <volume>29</volume>
            <issue>5</issue>
            <fpage>1268</fpage>
            <page-range>1268-1270</page-range>
            <pub-id pub-id-type="pmid">36635950</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149534.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Win</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Thein</surname>
                <given-names>KZ</given-names>
              </name>
              <name>
                <surname>Qdaisat</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Yeung</surname>
                <given-names>SJ</given-names>
              </name>
            </person-group>
            <article-title>Acute symptomatic hypocalcemia from immune checkpoint therapy-induced hypoparathyroidism.</article-title>
            <source>Am J Emerg Med</source>
            <year>2017</year>
            <month>Jul</month>
            <volume>35</volume>
            <issue>7</issue>
            <fpage>1039.e5</fpage>
            <page-range>1039.e5-1039.e7</page-range>
            <pub-id pub-id-type="pmid">28363614</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149534.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nalluru</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Piranavan</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ning</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ackula</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Siddiqui</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Trivedi</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Hypocalcemia with Immune Checkpoint Inhibitors: The Disparity among Various Reports.</article-title>
            <source>Int J Endocrinol</source>
            <year>2020</year>
            <volume>2020</volume>
            <fpage>7459268</fpage>
            <pub-id pub-id-type="pmid">32587615</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149534.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Delivanis</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Gustafson</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Bornschlegl</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Merten</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Kottschade</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Withers</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dietz</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Ryder</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Pembrolizumab-Induced Thyroiditis: Comprehensive Clinical Review and Insights Into Underlying Involved Mechanisms.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2017</year>
            <month>Aug</month>
            <day>01</day>
            <volume>102</volume>
            <issue>8</issue>
            <fpage>2770</fpage>
            <page-range>2770-2780</page-range>
            <pub-id pub-id-type="pmid">28609832</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149534.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schneider</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Naidoo</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Santomasso</surname>
                <given-names>BD</given-names>
              </name>
              <name>
                <surname>Lacchetti</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Adkins</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Anadkat</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Atkins</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Brassil</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Caterino</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Chau</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Davies</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Ernstoff</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Fecher</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ghosh</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jaiyesimi</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Mammen</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Naing</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nastoupil</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Phillips</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Porter</surname>
                <given-names>LD</given-names>
              </name>
              <name>
                <surname>Reichner</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Seigel</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Song</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Spira</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Suarez-Almazor</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Swami</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Vikas</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Weber</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Funchain</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bollin</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update.</article-title>
            <source>J Clin Oncol</source>
            <year>2021</year>
            <month>Dec</month>
            <day>20</day>
            <volume>39</volume>
            <issue>36</issue>
            <fpage>4073</fpage>
            <page-range>4073-4126</page-range>
            <pub-id pub-id-type="pmid">34724392</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149534.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Percik</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Criseno</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Adam</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Young</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Morganstein</surname>
                <given-names>DL</given-names>
              </name>
            </person-group>
            <article-title>Diagnostic criteria and proposed management of immune-related endocrinopathies following immune checkpoint inhibitor therapy for cancer.</article-title>
            <source>Endocr Connect</source>
            <year>2023</year>
            <month>May</month>
            <day>01</day>
            <volume>12</volume>
            <issue>5</issue>
            <pub-id pub-id-type="pmid">36884258</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
